Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Huangdai Tablets plus all-trans retinoic acid in acute promyelocytic leukemia
CTR20180254Phase 4Active
- Sponsor
- Anhui Tiankang Pharmaceutical
- Start
- Mar 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of Compound Huangdai Tablet in Acute promyelocytic leukaemia (APL), sponsored by Anhui Tiankang Pharmaceutical. Started Mar 2018; status: active.
02
Drugs
Compound Huangdai Tablet
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on CTR20180254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180254.